PT - JOURNAL ARTICLE AU - Itziar de Rojas AU - Sonia Moreno-Grau AU - Niccolò Tesi AU - Benjamin Grenier-Boley AU - Victor Andrade AU - Iris Jansen AU - Nancy L. Pedersen AU - Najada Stringa AU - Anna Zettergren AU - Isabel Hernández AU - Laura Montrreal AU - Carmen Antúnez AU - Anna Antonell AU - Rick M. Tankard AU - Joshua C. Bis AU - Rebecca Sims AU - Céline Bellenguez AU - Inés Quintela AU - Antonio González-Perez AU - Miguel Calero AU - Emilio Franco AU - Juan Macías AU - Rafael Blesa AU - Manuel Menéndez-González AU - Ana Frank-García AU - Jose Luís Royo AU - Fermín Moreno AU - Raquel Huerto AU - Miquel Baquero AU - Mónica Diez-Fairen AU - Carmen Lage AU - Sebastian Garcia-Madrona AU - Pablo García AU - Emilio Alarcón-Martín AU - Sergi Valero AU - Oscar Sotolongo-Grau AU - EADB, GR@ACE, DEGESCO, IGAP (ADGC, CHARGE, EADI, GERAD) and PGC-ALZ Consortia AU - Guillermo Garcia-Ribas AU - Pascual Sánchez-Juan AU - Pau Pastor AU - Jordi Pérez-Tur AU - Gerard Piñol-Ripoll AU - Adolfo Lopez de Munain AU - Jose María García-Alberca AU - María J. Bullido AU - Victoria Álvarez AU - Alberto Lleó AU - Luis M. Real AU - Pablo Mir AU - Miguel Medina AU - Philip Scheltens AU - Henne Holstege AU - Marta Marquié AU - María Eugenia Sáez AU - Ángel Carracedo AU - Philippe Amouyel AU - Julie Williams AU - Sudha Seshadri AU - Cornelia M. van Duijin AU - Karen A. Mather AU - Raquel Sánchez-Valle AU - Manuel Serrano-Ríos AU - Adelina Orellana AU - Lluís Tárraga AU - Kaj Blennow AU - Martijn A. Huisman AU - Ole A. Andreassen AU - Danielle Posthuma AU - Jordi Clarimón AU - Mercè Boada AU - Wiesje M. van der Flier AU - Alfredo Ramirez AU - Jean-Charles Lambert AU - Sven J. van der Lee AU - Agustín Ruiz TI - Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores AID - 10.1101/19012021 DP - 2019 Jan 01 TA - medRxiv PG - 19012021 4099 - http://medrxiv.org/content/early/2019/11/15/19012021.short 4100 - http://medrxiv.org/content/early/2019/11/15/19012021.full AB - BACKGROUND Disentangling the genetic constellation underlying Alzheimer’s disease (AD) is important. Doing so allows us to identify biological pathways underlying AD, point towards novel drug targets and use the variants for individualised risk predictions in disease modifying or prevention trials. In the present work we report on the largest genome-wide association study (GWAS) for AD risk to date and show the combined utility of proven AD loci for precision medicine using polygenic risk scores (PRS).METHODS Three sets of summary statistics were included in our meta-GWAS of AD: an Spanish case-control study (GR@ACE/DEGESCO study, n = 12,386), the case-control study of International Genomics of Alzheimer project (IGAP, n = 82,771) and the UK Biobank (UKB) AD-by-proxy case-control study (n=314,278). Using these resources, we performed a fixed-effects inverse-variance-weighted meta-analysis. Detected loci were confirmed in a replication study of 19,089 AD cases and 39,101 controls from 16 European-ancestry cohorts not previously used. We constructed a weighted PRS based on the 39 AD variants. PRS were generated by multiplying the genotype dosage of each risk allele for each variant by its respective weight, and then summing across all variants. We first validated it for AD in independent data (assessing effects of sub-threshold signal, diagnostic certainty, age at onset and sex) and tested its effect on risk (odds for disease) and age at onset in the GR@ACE/DEGESCO study.FINDINGS Using our meta-GWAS approach and follow-up analysis, we identified novel genome-wide significant associations of six genetic variants with AD risk (rs72835061-CHRNE, rs2154481-APP, rs876461-PRKD3/NDUFAF7, rs3935877-PLCG2 and two missense variants: rs34173062/rs34674752 in SHARPIN gene) and confirmed a stop codon mutation in the IL34 gene increasing the risk of AD (IL34-Tyr213Ter), and two other variants in PLCG2 and HS3ST1 regions. This brings the total number of genetic variants associated with AD to 39 (excluding APOE). The PRS based on these variants was associated with AD in an independent clinical AD-case control dataset (OR=1.30, per 1-SD increase in the PRS, 95%CI 1.18-1.44, p = 1.1×10−7), a similar effect to that in the GR@ACE/DEGESCO (OR=1.27, 95%CI 1.23-1.32, p = 7.4×10−39). We then explored the combined effects of these 39 variants in a PRS for AD risk and age-at-onset stratification in GR@ACE/DEGESCO. Excluding APOE, we observed a gradual risk increase over the 2% tiles; when comparing the extremes, those with the 2% highest risk had a 2.98-fold (95% CI 2.12–4.18, p = 3.2×10−10) increased risk compared to those with the 2% lowest risk (p = 5.9×10−10). Using the PRS we identified APOE ε33 carriers with a similar risk as APOE ε4 heterozygotes carriers, as well as APOE ε4 heterozygote carriers with a similar risk as APOE ε4 homozygote. Considering age at onset; there was a 9-year difference between median onset of AD the lowest risk group and the highest risk group (82 vs 73 years; p = 1.6×10−6); a 4-year median onset difference (81 vs 77 years; p = 6.9×10−5) within APOE e4 heterozygotes and a 5.5-year median onset difference (78.5 vs 73 years; p = 4.6×10−5) within APOE e4 carriers.INTERPRETATION We identified six novel genetic variants associated with AD-risk, among which one common APP variant. A PRS of all genetic loci reported to date could be a robust tool to predict the risk and age at onset of AD, beyond APOE alone. These properties make PRS instrumental in selecting individuals at risk in order to apply preventative strategies and might have potential use in diagnostic work-up.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria ‘La Caixa’, Fundació ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474 and PI19/01240. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER-‘Una manera de hacer Europa’). Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). 100-Plus study: This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW projectnumber 733050814) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot Applicable